Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia

Medecine et Maladies Infectieuses

Volumn 41, Issue 12, 2011, Pages 652-656

  Hochart, C ^a,c   Berthon, C ^a   Corm, S ^a,d   Gay, J ^a   Cliquennois, M ^a   Tricot, S ^a   Alfandari, S ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CENTRE HOSPITALIER DE TOURCOING   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Service d'Hématologie Clinique   (France)

Author keywords

Antibiotic monitoring; Antibiotic stewardship; Febrile neutropenia; Vancomycin

Indexed keywords

BETA LACTAM ANTIBIOTIC; CREATININE; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTERIAL INFECTIONS; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEVER; GUIDELINE ADHERENCE; HOSPITALS, UNIVERSITY; HUMANS; INAPPROPRIATE PRESCRIBING; INDUCTION CHEMOTHERAPY; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; LEUKEMIA, MYELOID; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 83355166795     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2011.09.014     Document Type: Article

References (15)

1. Howden B.P., Ward P.B., Charles P.G., Korman T.M., Fuller A., du Cros P., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004, 38:521-528.
2. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering R.C., Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402.
3. Rybak M., Lomaestro B., Rotschafer J.C., Moellering R., Craig W., Billeter M., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
4. Cordonnier C., Buzyn A., Leverger G., Herbrecht R., Hunault M., Leclercq R., et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003, 36:149-158.
5. Lortholary O., Lefort A., Tod M., Chomat A.M., Darras-Joly C., Cordonnier C. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect Dis 2008, 8:612-620. Club de reflexion sur les infections en oncohématologie.
6. Cometta A., Marchetti O., Calandra T. Empirical use of anti-Gram-positive antibiotics in febrile neutropaenic cancer patients with acute leukaemia. Eur J Cancer Suppl 2007, 5:23-31.
7. Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52(4):427-431.
8. Paul M., Yahav D., Fraser A., Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006, 57:176-189.
9. Vardakas K.Z., Samonis G., Chrysanthopoulou S.A., Bliziotis I.A., Falagas M.E. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005, 5:431-439.
10. Cometta A., Kern W.V., De Bock R., Paesmans M., Vandenbergh M., Crokaert F., et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003, 37:382-389.
11. American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
12. Rybak M.J., Lomaestro B.M., Rotscahfer J.C., Moellering R.C., Craig W.A., Billeter M., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327.
13. Fernández de Gatta M.M., Fruns I., Hernandez J.M., Caballero D., San Miguel J.F., Martínez Lanao J., et al. Vancomycin pharmacokinetics and dose requirements in hematologic malignancies. Clin Pharm 1993, 12:515-520.
14. Robert J.A., Taccone F.S., Udy A.A., Vincent J.L., Jacobs F., Lipman J. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011, 55:2704-2709.
15. Wysocki M., Delatour F., Faurisson F., Rauss A., Pean Y., Misset B., et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001, 45:2460-2467.